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Abstract: The identification of BRCA mutations plays a crucial role in the management of hereditary
cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC) patients is
not universally introduced in clinical practice. A retrospective analysis was conducted, firstly, to
evaluate the rate of BRCA-positive families among those presenting a family history of PC besides
breast and/or ovarian cancer. Secondly, the relationship between BRCA pathogenic variants and PC
risk was evaluated. Finally, the characteristics of PC developed in BRCA families were described.
Among 5143 family trees reporting breast and/or ovarian cancer cases, 392 showed a family history
of PC. A total of 35 families (24.5% selected by the Modena Criteria and 21.3% by the NCCN Criteria)
were positive to BRCA testing. Among the BRCA1 mutations, 36.8% were found within a region
defined by c.3239–c.3917, whilst 43.7% of BRCA2 mutations were located within c.7180–c.8248. This
study confirmed that an increase in the rate of positive tests in families with PC when associated
to breast and/or ovarian tumors. Moreover, this analysis indicated two possible Pancreatic Cancer
Cluster Regions that should be verified in future research. Finally, PC in families with breast and/or
ovarian cancer history, particularly in BRCA families, were diagnosed at younger age and showed
better one-year overall survival.
Keywords: BRCA genes; pancreatic cancer; genetic testing; hereditary cancer; homologous
recombination
1. Introduction
The BRCA1 and BRCA2 genes encode for proteins involved in tumor suppression. Particularly, the
BRCA genes are involved in the repair of DNA double-stranded breaks (DSBs) through the mechanism
of homologous recombination (HR) [1]. Currently, hundreds of different mutations have been identified
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in both BRCA1 and BRCA2 genes, and individuals carrying these mutations in parental germline cells
showed an increased susceptibility to several solid cancers. Tumors developing in these individuals are
classified as hereditary cancers. Based on this information, when an individual is suspected of being at
risk of hereditary cancer according to his personal and family cancer history, a genetic counseling and
possibly a genetic testing should be offered [2–4].
Overall, BRCA1/2 mutation carriers present an increased risk for breast cancer (52–72% in BRCA1,
45–84% in BRCA2), ovarian cancer (39–63% in BRCA1, 11–27% in BRCA2), prostate cancer (3.4-fold
increased risk in BRCA1, 8.6-fold increased risk in BRCA2), and pancreatic cancer (1–3% in BRCA1,
2–7% in BRCA2) [5–9]. Moreover, an increased frequency of other malignancies, such as melanoma
and other gastro-intestinal tumors, has been reported in families with mutations in the BRCA2 gene [7].
As a result, several National and International Guidelines published BRCA testing criteria for the
selection of the best candidates for genetic testing. The American National Comprehensive Cancer
Network (NCCN) Guidelines present one of the highest sensitivity in BRCA carrier detection [10,11],
and include personal and family history of breast, ovarian, prostate, and pancreatic cancers among the
BRCA testing criteria, as reported in Table 1. On the other hand, according to the Italian Association of
Medical Oncology (AIOM) Guidelines, which reflect the Modena Criteria [12–14] listed in Table 2, the
Italian National Health Service provides free BRCA diagnostic tests exclusively to breast and ovarian
cancer patients and healthy individuals with an estimated risk of carrying a BRCA mutation ≥ 40%.
All the Italian criteria are included in the NCCN Guidelines.
The identification of a mutation in BRCA genes plays a crucial role in the management of
hereditary cancer prevention, diagnosis, and treatment. In healthy BRCA carriers, the detection of a
mutation may justify more intensive and personalized surveillance programs [15], chemo-preventive
approaches [16], and prophylactic surgery [17] that would not otherwise be justified by family history
alone. On the other hand, the identification of a mutation in patients already affected by cancer
may provide the fundamental knowledge of the pathogenesis of these tumors, thereby guiding
treatment choices. In particular the impairment of the HR pathway is thought to confer major
sensitivity to platinum agents, and the inhibition of poly (ADP-ribose) polymerase (PARP) by the use
of PARP inhibitors, resulting in the persistence of DNA damage and in cell cycle arrest [1,18]. Despite
these considerations, BRCA-testing in pancreatic cancer patients and their families is not universally
introduced in clinical practice. Due to the high cost of genetic tests, especially in those countries where
genetic testing is freely available, BRCA1/2-testing has traditionally been restricted to individuals
with a high risk of being a carrier.
The purposes of our retrospective analysis were: Firstly, to evaluate the rate of BRCA-positive
families among those presenting a family history of pancreatic cancer besides breast and/or ovarian
cancer; secondly, to evaluate whether a relationship exists between BRCA pathogenic variants and
pancreatic cancer risk in the family and, finally, to explore the characteristics of pancreatic cancers
developed in BRCA positive families.
2. Results
2.1. Family Characteristics
From January 1997 to May 2017, 5143 families with a positive family history for breast and/or
ovarian cancer were counseled and taken in charge by the Modena Family Cancer Clinic (MFCC).
Among these, 5143 family trees stored in our archives, 392 (7.6%) also reported a family history of
pancreatic cancer (Figure 1). In particular, 6 families (one of which BRCA1 positive) showed three
pancreatic cancer cases, and 31 families (4 of which BRCA1 positive and 2 of which BRCA2 positive)
showed two pancreatic cancer cases.
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Figure 1. Study flow chart. 
All these families (100%) were candidate to BRCA testing according to the NCCN Guidelines 
2019, whereas only 217 (55.4%) of these families were candidate to BRCA testing according to the 
Modena Criteria. Among families selected using the NCCN Criteria (Table 1), 69 (17.6%) families 
showed an early onset breast cancer (diagnosis at ≤ 35 years) in the pedigree, 13 (3.3%) had a male 
breast cancer, 71 (18.1%) showed at least one case of ovarian cancer, while in 86 (21.9%) families 
pancreatic cancer was associated to only one sporadic breast cancer (diagnosis at > 40 years). On the 
other hand, among families selected by the Modena Criteria, 69 (31.8%) families showed an early 
onset breast cancer (diagnosed at ≤ 35 years) in the pedigree, 13 (5.9%) had a male breast cancer, 70 
(32.2%) showed at least one case of ovarian cancer, while pancreatic cancer was never associated to 
sporadic breast cancer (diagnosed at > 40 years). 
Table 1. The NCCN BRCA testing criteria (NCCN Guidelines Version 2.2019). 
Breast Cancer Diagnosed ≤ 45 Years 
OC, fallopian tube or primary peritoneal cancer at any age. 
Male breast cancer. 
Triple negative BC diagnosed ≤ 60 years. 
BC diagnosed 46–50 years with a second BC primary at any age. 
BC diagnosed 46–50 years with ≥ 1 close relative with BC or prostate cancer (GS ≥ 7) or with unknown or 
limited family history. 
BC diagnosed at any age with ≥ 1 close relative with BC ≤ 50 years or OC or male BC or metastatic prostate 
cancer or pancreatic cancer. 
BC diagnosed at any age with ≥ 2 additional diagnosis of BC at any age in patient and/or in close blood 
relatives. 
Personal history of BC or prostate cancer (GS ≥ 7) with Ashkenazi Jewish ancestry. 
Pancreatic cancer. 
Metastatic prostate cancer. 
Prostate cancer (GS ≥ 7) at any age with ≥1 close blood relative with OC at any age or pancreatic cancer or 
metastatic prostate cancer or BC ≤ 50 years. 
Prostate cancer (GS ≥ 7) at any age with ≥ 2 close blood relatives with BC or prostate cancer (any grade). 
BRCA 1/2 pathogenic/likely pathogenic mutation detected by tumor profiling of any tumor type in the 
absence of germline pathogenic/likely pathogenic variant analysis. 
Regardless of family history, some individuals with a BRCA-related cancer may benefit from genetic 
testing to determinate eligibility for targeted treatment. 
An individual who does not meet the other criteria but with ≥ 1 first- or second-degree blood relative 
meeting any of the above criteria. The significant limitations of interpreting test results for an unaffected 
individual should be discussed. 
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All these families (100%) were candidate to BRCA testing according to the NCCN Guidelines 2019,
whereas only 217 (55.4%) of these families were candidate to BRCA testing according to the Modena
Criteria. Among families selected using the NCCN Criteria (Table 1), 69 (17.6%) families showed an
early onset breast cancer (diagnosis at ≤ 35 years) in the pedigree, 13 (3.3%) had a male breast cancer,
71 (18.1%) showed at least one case of ovarian cancer, while in 86 (21.9%) families pancreatic cancer
was associated to only one sporadic breast cancer (diagnosis at > 40 years). On the other hand, among
families selected by the Modena Criteria, 69 (31.8%) families showed an early onset breast cancer
(diagnosed at ≤ 35 years) in the pedigree, 13 (5.9%) had a male breast cancer, 70 (32.2%) showed at
least one case of ovarian cancer, while pancreatic cancer was never associated to sporadic breast cancer
(diagnosed at > 40 years).
Table 1. The NCCN BRCA testing criteria (NCCN Guidelines Version 2.2019).
Breast Cancer Diagnosed≤ 45 Years
OC, fallopian tube or primary peritoneal cancer at any age.
Male breast cancer.
Triple negative BC diagnosed ≤ 60 years.
B osed 46–50 years with a second BC prima y at any age.
B iagnosed 46–50 years with ≥ 1 close relative with BC or prostate cancer (GS ≥ 7) or with unknown or limited
family history.
BC diagnosed at any age with ≥ 1 close relative with BC ≤ 50 years or OC or male BC or metastatic prostate cancer or
pancreatic cancer.
BC diagnosed at any age with ≥ 2 additional diagnosis of BC at any age in patient and/or in close blood relatives.
Personal hi tory of BC or prostate cancer (GS ≥ 7) with Ashkenazi Jewish anc stry.
Pancreatic cancer.
Metastatic prostate cancer.
Prostate cancer (GS ≥ 7) at any age with ≥1 close blood relative with OC at any age or pancreatic cancer or metastatic
prostate cancer or BC ≤ 50 years.
Prosta e cancer (GS ≥ 7) at any age with ≥ 2 close blood relatives with BC or prostate cancer (any grade).
BRCA 1/2 pathogenic/likely pathogenic mutation detected by tumor profiling of any tumor type in the absence of
germline pathogenic/likely pathogenic variant analysis.
Regardless of family history, some individuals with a BRCA-related cancer may benefit from genetic testing to
determinate eligibility for targeted treatment.
An individual who does not meet the other criteri but with≥ 1 first- or second-degree blood relative meeting any of the
above criteria. The significant limitations of interpreting test results for an unaffected individual should be discussed.
BC: Breast Cancer; OC: ovarian cancer; GS: Gleason Score; Close blood relatives include first-, second- a d third-
degree relatives on same side of family.
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One hundred and 43 (65.9%) families selected according to the Modena Criteria were subject
to BRCA testing, and 19 BRCA1 mutations and 16 BRCA2 mutations were identified (detection rate
24.5%). On the other hand, 164 (41.8%) families that were selected with the NCCN Criteria were subject
to BRCA testing and showed a detection rate of 21.3%.
2.2. BRCA Pathogenic Variants and Pancreatic Cancer Risk
The BRCA mutations detected in families with history of pancreatic cancer are reported in
Figures 2 and 3. Ten out of 19 (52.6%) BRCA1 mutations were located in EXON10. On the other hand,
the most mutated exon in BRCA2 was EXON11 (5 out of 16, 31.2%), followed by EXON18 (3 out of
16, 18.7%). In particular, 7 out of 19 (36.8%) BRCA1 mutations were found within a region defined by
c.3239–c.3917 (Figure 2), while 7 out of 16 (43.7%) BRCA2 mutations were located within the interval
c.7180–c.8248 (Figure 3). Finally, the most common BRCA1 mutation types were frame-shift mutations
(9 out of 19, 47.3%), followed by missense mutations (5 out of 19, 26.3%). With regards to BRCA2, the
most frequent mutation types were frame-shift mutations (10 out of 16, 62.5%), followed by nonsense
mutations (5 out of 16, 31.2%).
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Table 2. The Modena Criteria (AIOM Guidelines 2018).
BC and OC Diagnosed in The Same Patient
OC, fallopian tube or primary peritoneal cancer (excluded mucinous and borderline) at any age.
Male Breast Cancer.
Triple negative BC diagnosed ≤60 years.
BC diagnosed ≤ 35 years.
At least 1 BC and at least 1 OC.
At least 2 first-degree blood relative with BC, at least one diagnosed ≤ 40 years or bilateral.
Healthy individuals with an estimated risk of carrying a BRCA mutation ≥ 40%, calculated with the BRCAPro
risk calculator (Version CaGene6)
BC: Breast Cancer; OC: ovarian cancer.
2.3. Characteristics of Pancreatic Cancers Developed in BRCA Families
The average age for pancreatic cancer diagnosis was 66 (range 20–94) in the overall study
population, 65 (46–85) in the 19 BRCA1 positive families and 66 (range 49–80) in the 16 BRCA2
positive families. Therefore, pancreatic cancer patients in our study population were diagnosed at
younger ages than the general population, where the average age for diagnosis is 70, according to the
Surveillance, Epidemiology and End Results (SEER) program [19] (Table 3).
The one-year OS rate was 42% in the overall study population, 42.8% in BRCA1 positive families
and 61.5% in BRCA2 positive families. Therefore, pancreatic cancer patients in our study population
showed a higher one-year OS rate than the general population, where the rate is 23% according to the
Italian Cancer Registry [20]. Finally, 5-year OS rate was 6.6% in the overall study population, 7.1% in
BRCA1 positive families and 0% in BRCA2 positive families. Therefore, pancreatic cancer patients in
our study population showed lower 5-year OS rate than the general population where the rate is 8.1%
according to the Italian Cancer Registry [21] (Table 3).
Table 3. Pancreatic cancer characteristics in our sample and in the general population [20–22].
Overall Study
Population
(392 patients)
BRCA1 Families
(19 patients)
BRCA2 families
(16 patients)
General
Population
(Cancer Registries)
Age at Pancreatic
Cancer Diagnosis
65.8 (20–94)
(31 unknown)
65.2 (46–85)
(3 unknown)
66.3 (49–80)
(1 unknown) 70 [18]
one-year OS 42%(59 unknown)
42.8%
(5 unknown)
61.5%
(3 unknown) 23% [19]
5-year OS 6.6%(59 unknown)
7.1%
(5 unknown)
0%
(3 unknown) 8.1% [20]
3. Discussion
Pancreatic ductal adenocarcinoma has a poor prognosis, with a 5-year survival rate of only 5% [22].
Approximately 4% of all patients with pancreatic ductal adenocarcinoma have an underlying gene
defect, with ATM, BRCA1/2, and PALB2 being the most commonly affected genes [23–25]. Overall,
only 3–10% of patients have a positive family history for this cancer [26]. In particular, recent studies
found deleterious germline mutations in pancreatic cancer predisposition genes in 3.9–7.7% sporadic
pancreatic adenocarcinomas, and around 45% of these mutations were in one of the BRCA genes [27–29].
Interestingly, in these studies germline mutations were identified in patients with pancreatic cancer
without a significant family history of cancer. This highlights the limitations of many current genetic
testing criteria for patient selection. Following a systematic review of the literature published from
January 1998 to June 2018, a recently published American Society of Clinical Oncology (ASCO)
Provisional Clinical Opinion states that all patients diagnosed with pancreatic adenocarcinoma should
be assessed for the risk of hereditary syndromes, known to be associated with an increased risk for
pancreatic adenocarcinoma [30].
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Currently, surgical resection is the only potentially curative treatment for pancreatic ductal
adenocarcinoma, but in approximately 80% of symptomatic patients at diagnosis, the tumor is already
unresectable. Improvements in the resectability of tumors requires the detection of tumors at an earlier
stage; therefore, there is an urgent need to find effective screening programs especially for individuals
at an increased family risk. Surveillance programs based on annual magnetic resonance imaging,
magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound, recently demonstrated
an increase in the detection of pancreatic tumors at a resectable stage in CDNK2A mutation carriers [31].
Therefore, the identification of a mutation in pancreatic cancer susceptibility genes may justify more
intensive and personalized surveillance programs [32].
In an attempt to determine the incidence and the characteristics of BRCA-associated pancreatic
cancers, we reviewed our institution’s experience. A high rate of germline BRCA1 and BRCA2
mutations was detected in our retrospective analysis of 392 families with pancreatic cancer associated
with breast and/or ovarian cancer. In particular, the detection rate was 21.3% when the NCCN
Guidelines were applied, and 24.5% with the Modena Criteria. Overall, the detection rate of BRCA
mutation when applying the Modena Criteria in our daily clinical experience is 17%. Therefore, our
retrospective study confirmed an increased rate of positive BRCA1/2 test in families with pancreatic
cancers when associated to breast and/or ovarian tumors. Moreover, although a lower rate of families
were tested in the NCCN group, the Modena Criteria seems to be more cost-effective than the NCCN
Guidelines in the identification of individuals carrying the mutation. Interestingly, our analysis also
shows that only 7 out of 35 (20%) BRCA-associated pancreatic cancer patients presented a family
history of pancreatic cancer. While the approval of PARP inhibitors in pancreatic cancer treatment, and
the extension of genetic testing to all candidate pancreatic cancer patients for those treatments is still
underway, our findings support the introduction of pancreatic cancer among the testing criteria, at
least when associated to family history of breast or ovarian cancer.
The BRCA mutations, detected in our families with a history of pancreatic cancer, were more
frequently located in the longest exon of each gene, EXON10 of the BRCA1 gene and in the EXON11 of
the BRCA2 gene. Interestingly, we identified two nucleotide intervals presenting a higher incidence
of mutations: The BRCA1 region is defined by c.3239–c.3917 and the BRCA2 region is located within
c.7180–c.8248. These intervals correspond to, neither the previously identified Breast Cancer Cluster
Regions (BCCR), nor the Ovarian Cancer Cluster Regions (OCCR) of BRCA1, and only marginally
overlap with the BCCRs and the OCCRs of BRCA2 [33]. As for breast and ovarian cancer, it is likely that
mutations in a specific gene region may influence the risk and the characteristics of pancreatic cancer
that is developed by BRCA mutation carriers. Our findings indicated two possible Pancreatic Cancer
Cluster Regions that should be verified in larger cohort of BRCA-associated pancreatic cancer patients.
As for the BRCA-associated breast and ovarian cancer, BRCA carriers that were affected by
pancreatic cancer were demonstrated to be optimal candidates to platinum-based therapy and PARP
inhibitors [34–38]. For this reason, along with the early diagnosis provided by the surveillance
programs, the identification of a BRCA mutation in pancreatic cancer patients should assume a central
role in the improvement of the outcome for these patients.
According to our results, pancreatic cancers in families with breast and/or ovarian cancer history
are diagnosed at a younger age and show better one-year OS than those developed in the general
population. These results may be justified by the presence of germ-line mutations that predispose
these families to hereditary pancreatic, breast, and ovarian tumors. Interestingly, in line with previous
literature [37,39], these findings are also confirmed in the BRCA families. Particularly, the age for
pancreatic cancer diagnosis in BRCA1 families is significantly lower than in BRCA2 families and general
populations, whereas short-term prognosis for patients in BRCA2 families is significantly better than
for other groups of patients. Similar results were previously observed in the recently published POSH
study [40], in which BRCA-associated triple-negative breast cancer showed a better survival rate over
the first few years after diagnosis. This early survival advantage was also previously observed among
BRCA patients with ovarian cancer [41]. This short-term survival advantage might reflect greater
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sensitivity of BRCA-mutant cancers to chemotherapy, particularly in pancreatic and ovarian cancers,
that are usually treated with platinum-based regimens in the first line setting. However, his survival
advantage is likely to be lost lost because of the treatment resistance mechanisms that can develop,
such as the occurrence of secondary BRCA mutations that restore the BRCA function and HR activity.
There are certainly some limitations to our retrospective analysis. It should be noted that in our
study, the cancer family history was collected from the anamnesis of women who accessed the MFCC,
because of their breast and/or ovarian family history. Therefore, a bias in data collection could be
present, since there is a chance, that some cancer cases and their outcome, were wrongly reported by
patients’ relatives and, therefore, misclassified. For the same reason, we do not have any information
regarding surgical and medical treatments undergone by these pancreatic cancer patients. Finally, since
most pancreatic cancer patients were not alive at the time of genetic counseling, it was not possible to
verify which pancreatic cancer patients in BRCA positive families were actually BRCA carriers.
4. Material and Methods
4.1. Study Population and Design
Since 1995, the MFCC takes charge of women with a family history of breast and/or ovarian cancer.
According to the Modena Criteria [12,13] and, more recently, by the Tyrer-Cuzick model [17], women
are classified in risk categories and are included in personalized surveillance programs. Moreover,
women or their relatives who meet the Modena Criteria for genetic testing can undergo the BRCA test
and, according to the result, may access risk-reducing surgeries [18], chemo-preventive studies [16] or
more intensive surveillance programs [15]. During pre-test counseling, family and personal history
of cancer is collected and a family tree is drawn. Finally, after the post-test counseling, a copy of all
patients’ documents and reports are stored in the archive of the MFCC.
For the purposes of our study, we retrospectively identified families with at least one pancreatic
cancer reported in the family tree and registered them in our archive. Then, each family was analyzed
according to the NCCN BRCA testing Criteria and the Modena Criteria, in order to evaluate the number
of candidate families to genetic testing in each group. Finally, we evaluated the rate of positive tests in
each group, defining the detection rate of BRCA mutations according to the different criteria applied.
In addition, we looked at the BRCA pathogenic variants detected, to investigate a possible
association between the gene region affected by mutation and pancreatic cancer risk. Finally, we
analyzed age at diagnosis of pancreatic cancer, the one-year and 5-year overall survival rate in families
with BRCA mutation compared to the general population.
4.2. BRCA Testing Procedures
Before 2014, the genetic testing of BRCA1 and BRCA2 genes in our institution was carried out by
direct Sanger sequencing, whilst after 2014, it was performed using next generation sequencing (NGS).
With both methods, the molecular test was performed on genomic DNA, isolated from fresh peripheral
blood samples, encompassing the entire coding region and adjacent intronic splice-site consensus
sequences of BRCA genes. The NGS workflow benefited from the use of the Ion AmpliSeqTM (Thermo
Fisher Scientific, Waltham, MA, USA) technology that was handled initially with a semi-automated
and subsequently, with a fully automated procedure for multiplex PCR-based library preparation
and sequencing on the Ion Torrent platforms (Thermo Fisher Scientific, Waltham, MA, USA). Sanger
sequencing was routinely performed to validate candidate mutations, as long as multiplex ligation
probe amplification (MLPA, MRC-Holland, Amsterdam, the Netherlands) was carried out to detect
copy number variations. Sequences alignment, base calling, variants filtering, and annotation
process took advantage of the Torrent Software Suite (Thermo Scientific) and of a custom designed
bio-informatic pipeline, as described in previously published works [42,43].
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5. Conclusions
Our study suggests the possibility of an improvement in the National and International BRCA
testing criteria by including pancreatic cancer cases among the criteria. Further research should
be directed to evaluating whether the detection of a BRCA mutation could improve the outcome
of pancreatic cancer patients, by the introduction of prevention strategies and tailored treatments.
Moreover, since the risk of pancreatic cancer increases 10-fold in BRCA carriers, more effort is needed
to identify which mutations are associated with a significantly increased risk for this tumor.
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